Achieve Life Sciences (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments, showing strong recent technical momentum. Shares recently hit a 3-year high earlier in July. Despite robust technicals, ACHV remains highly speculative, as it has not yet begun monetizing its research pipeline.
Valued at $685 million, Achieve Life Sciences (ACHV) is a pharmaceutical company. It develops and commercializes cytisinicline treatment to help people battling nicotine addiction. I found today's Chart of the Day by using Barchart's powerful screening functions to sort for stocks with the highest technical buy signals and superior current momentum.
I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. The Trend Seeker issued a new "Buy" signal on June 25. Since then, the stock has gained 16.84%.
A $20 Billion Reason Why Intel Stock Is in Focus Dear Intel Stock Fans, Mark Your Calendars for August 12 Ahead of Nebius Earnings, Here's What Barchart Data Says Comes Next for NBIS Stock Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Editor's Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates.
The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock. Achieve Life Sciences scored a 3-year high of $7.11 on July 1.
Achieve Life Sciences has a Weighted Alpha of 122.15. ACHV has a 100% "Buy" opinion from Barchart. The stock has gained 173.36% over the past 52 weeks.
Extract — continue reading at the source.
